Treatment Information

Back

Rectal Cancer treatment details. Chemotherapy.

National Cancer Center Hospital, Tokyo, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:3City/State/Province:Tokyo
Treatments:ChemotherapyHospital:National Cancer Center Hospital
Drugs:Journal:Link
Date:Jun 2004

Description:

Patients: This Phase II study involved 38 patients with previously untreated metastatic colorectal carcinoma.

Treatment: The treatment consisted of oral fluoropyrimidine S-1 (a combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate).

Toxicity: Grade 3 toxicities included: anemia, neutropenia, diarrhea, and abnormal bilirubin levels. Grade 1 or 2 toxicities included: myelosuppression and gastrointestinal toxicity;.

Results: The median survival time was 358 days (11.8 months).

Support: The study was supported by Taiho Pharmaceutical Co. Taiho Pharmaceutical Co. manufactures fluoropyrimidine S-1.

Correspondence: Kuniaki Shirao, MD





Back